Idebenone is the leading treatment for LHON, a rare mitochondrial eye disease that causes rapid loss of central vision. As a synthetic analogue of Coenzyme Q10, idebenone supports mitochondrial energy production and reduces oxidative damage in retinal ganglion cells, helping preserve and potentially improve visual function in affected patients. Clinical evidence shows that early initiation of idebenone therapy can result in meaningful benefits in visual acuity, especially when started soon after symptom onset.
Email:uup_115@yahoo.com
Phone:858-964-0750